JWS
KNSA icon

Juncture Wealth Strategies’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Juncture Wealth Strategies’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.31M Sell
17,549
-275
-2% -$20.2K 0.34% 58
2026
Q2 		$1.14M Buy
17,824
+8,354
+88% +$433K 0.3% 60
2026
Q1 		$456K Buy
9,470
+1,324
+16% +$58.7K 0.15% 81
2025
Q4 		$336K Buy
8,146
+1,282
+19% +$51.4K 0.11% 94
2025
Q3 		$267K Buy
+6,864
New +$223K 0.09% 112

Other funds holding KNSA

TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Juncture Wealth Strategies's KNSA Position: Q3 2026 in Review

Juncture Wealth Strategies reduced its Kiniksa Pharmaceuticals (KNSA) stake by 1.5% in Q3 2026, selling an estimated $20.2K and leaving 17,549 shares worth $1.31M. The position accounts for 0.34% of the portfolio, ranked #58.

Juncture Wealth Strategies first reported a position in KNSA in Q3 2025 and has held it in 5 quarters since. 8 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Juncture Wealth Strategies held 17,549 shares of Kiniksa Pharmaceuticals worth $1.31M as of Q3 2026.
  • Juncture Wealth Strategies sold 275 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $20.2K.
  • Kiniksa Pharmaceuticals made up 0.34% of Juncture Wealth Strategies's portfolio in Q3 2026, its #58 holding.
  • Juncture Wealth Strategies first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 8 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Juncture Wealth Strategies's 13F filing for Q3 2026, filed 6 Oct 2026.